We are pleased to announce that the Translational Lung Cancer Research (TLCR) has attained its latest impact factor for the 2025 citation year: 3.4 (Figure 1).
Figure 1 Journal Impact Factor of TLCR
Translational Lung Cancer Research (TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is published by AME Publishing Company, with support from Wolters Kluwer (the journal content will be made available on Wolters Kluwer Health’s Lippincott and Ovid platforms). It is an international, peer-reviewed, open-access journal which was founded in March 2012. TLCR is indexed by Web of Science [Science Citation Index Expanded (SCIE)], PubMed/PubMed Central, Scopus and the Chemical Abstracts Service (CAS) Databases. TLCR is dedicated to focus on cutting-edge developments at the transition from preclinical to clinical research and thus closes the gap between “bench and bedside”. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer and related thoracic diseases. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer and relevant thoracic diseases. It is published quarterly (Mar. 2012 - Jan. 2013), bimonthly (Feb. 2013 - Dec. 2020), monthly (Jan. 2021 -) and openly distributed worldwide.
We strive to follow the best practices in publishing. The announcement of the journal’s latest impact factor is not only a significant achievement for the journal but also the recognition of its more significant scientific reach. Here, we would like to extend our heartfelt gratitude to all our Editorial Board Members, Guest Editors, Authors, and Reviewers for their significant contributions.
We look forward to the continuous cooperation with all the individuals mentioned above and those who are interested in lung cancer research to bring more exciting content to readers in the coming future.
2025 Journal Impact Factors of AME journals
We are also pleased to share the latest impact factors of all journals published under AME Publishing Company (Table 1).
- 37 AME journals received a Journal Impact Factor (JIF) this year, with three journals receiving their first JIF
- 12 journals have one or more categories ranked in Q1 or Q2
These achievements reflect the continuous growth and academic influence of our journal portfolio. We sincerely thank all contributors across our journals for their dedication and support.
Table 1 2025 Journal Impact Factors of AME journals
Editorial Office
Translational Lung Cancer Research